Validation of a novel methodology for endpoints assessing response to lymphoma treatment in real-world studies
Ended Definitive Contract Awarded Last action
- Contract number
- 75F40121C00134
- Awardee
-
Cardinal Health 127 Inc. UEI JE8BA2YTP569 Part of Cardinal Health, Inc.
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $727,362
Award facts
- Opportunity
-
- FY21 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Solicitation · FDABAA2100123 · Posted Nov 20, 2020
- Contract value 100% obligated
- $727,361.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$22,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $749,362 |
About this award
The U.S. Food and Drug Administration (FDA) awarded a $727,361.96 firm fixed-price contract to Cardinal Health 127 Inc., a subsidiary of Cardinal Health, Inc., to validate a novel methodology for assessing response to lymphoma treatment in real-world studies. This contract is not set aside.
The contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which seeks research and development proposals across several areas to modernize regulatory science and support the FDA's mission. As an indefinite delivery/indefinite quantity contract vehicle, the BAA facilitates ongoing research to support FDA regulatory functions on an as-needed basis. The contract has a performance period through March 22, 2024.
Cardinal Health, a global healthcare services and products company, primarily provides pharmaceutical distribution services to the U.S. military and Department of Veterans Affairs under prime federal contracts. This award aligns with the company's nuclear pharmacy expertise and distribution infrastructure supporting medical imaging procedures at VA healthcare facilities.
Quick answers
Who was awarded contract 75F40121C00134?
75F40121C00134 was awarded to Cardinal Health 127 Inc. by Food and Drug Administration (Department of Health and Human Services) on September 27, 2021.
How much is contract 75F40121C00134 worth?
The government has obligated $727,362 on 75F40121C00134.
Was contract 75F40121C00134 competed?
The extent of competition for 75F40121C00134 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award